| Literature DB >> 26735326 |
Marianne Labussière1,2,3, Caroline Cheneau1,2,3, Claudia Prahst4,5, Jaime Gállego Pérez-Larraya6, Patrizia Farina6, Giuseppe Lombardi6, Karima Mokhtari1,2,3,7,8, Amithys Rahimian8, Jean-Yves Delattre1,2,3,6,8, Anne Eichmann4,5, Marc Sanson1,2,3,6,8.
Abstract
Despite encouraging response rate of bevacizumab (BVZ) in recurrent glioblastoma, many patients do not respond to this schedule and most of the responders develop an early relapse. Plasma concentrations of VEGF, PlGF, Ang2, and sTie2 were assessed by ELISA before and during BVZ treatment in seventy patients. Baseline levels of VEGF-A, and PlGF were higher in patients than in healthy volunteers, whereas no difference was found for Ang2, and sTie2. No biomarker at baseline was associated with response, PFS or OS. At recurrence, the authors observed an increase of Ang2 suggesting that Ang2/sTie2 could be involved in the resistance to BVZ.Entities:
Keywords: Ang2; Glioblastoma; bevacizumab; plasma biomarkers
Mesh：
Substances：
Year: 2016 PMID： 26735326 DOI： 10.3109/07357907.2015.1088948
Source DB: PubMed Journal: Cancer Invest ISSN： 0735-7907 Impact factor: 2.176